Crossmark

Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience

Crossref DOI link: https://doi.org/10.1016/j.ad.2022.05.035

Published Print: 2023-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Arroyo-Andrés, J.

Falkenhain-López, D.

Agud-Dios, M.

Rivera-Díaz, R.
License Information

Text and Data Mining valid from 2023-04-01

Version of Record valid from 2022-12-14
More Information

This article is maintained by: Elsevier

Article Title: Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2022.05.035

Content Type: simple-article

Copyright: © 2022 AEDV. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below